These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19497337)

  • 21. The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.
    Clark SD
    Handb Exp Pharmacol; 2022; 271():525-546. PubMed ID: 33459877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide kappa opioid receptor ligands: potential for drug development.
    Aldrich JV; McLaughlin JP
    AAPS J; 2009 Jun; 11(2):312-22. PubMed ID: 19430912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons.
    Margolis EB; Hjelmstad GO; Bonci A; Fields HL
    J Neurosci; 2003 Nov; 23(31):9981-6. PubMed ID: 14602811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid receptors: distinct roles in mood disorders.
    Lutz PE; Kieffer BL
    Trends Neurosci; 2013 Mar; 36(3):195-206. PubMed ID: 23219016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of κ opioid receptor antagonists.
    Carroll FI; Carlezon WA
    J Med Chem; 2013 Mar; 56(6):2178-95. PubMed ID: 23360448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch from excitatory to inhibitory actions of ethanol on dopamine levels after chronic exposure: Role of kappa opioid receptors.
    Karkhanis AN; Huggins KN; Rose JH; Jones SR
    Neuropharmacology; 2016 Nov; 110(Pt A):190-197. PubMed ID: 27450094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
    Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
    J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.
    Dogra S; Yadav PN
    Eur J Pharmacol; 2015 Sep; 763(Pt B):184-90. PubMed ID: 26164787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).
    Guerrero M; Urbano M; Kim EK; Gamo AM; Riley S; Abgaryan L; Leaf N; Van Orden LJ; Brown SJ; Xie JY; Porreca F; Cameron MD; Rosen H; Roberts E
    J Med Chem; 2019 Feb; 62(4):1761-1780. PubMed ID: 30707578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.
    Anderson RI; Becker HC
    Alcohol Clin Exp Res; 2017 Aug; 41(8):1402-1418. PubMed ID: 28425121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction.
    Chartoff EH; Mavrikaki M
    Front Neurosci; 2015; 9():466. PubMed ID: 26733781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
    Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
    Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
    PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.
    Banks ML
    Handb Exp Pharmacol; 2020; 258():147-165. PubMed ID: 31463605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development.
    Aldrich JV; McLaughlin JP
    Handb Exp Pharmacol; 2022; 271():197-220. PubMed ID: 34463847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
    Ko MC; Husbands SM
    J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.
    Xie JY; De Felice M; Kopruszinski CM; Eyde N; LaVigne J; Remeniuk B; Hernandez P; Yue X; Goshima N; Ossipov M; King T; Streicher JM; Navratilova E; Dodick D; Rosen H; Roberts E; Porreca F
    Cephalalgia; 2017 Jul; 37(8):780-794. PubMed ID: 28376659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination.
    Mei F; Mayoral SR; Nobuta H; Wang F; Desponts C; Lorrain DS; Xiao L; Green AJ; Rowitch D; Whistler J; Chan JR
    J Neurosci; 2016 Jul; 36(30):7925-35. PubMed ID: 27466337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography.
    Placzek MS
    Handb Exp Pharmacol; 2022; 271():547-577. PubMed ID: 34363128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.